We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.
Similar Posts
Fixing Your Nervous System Dysregulation May Fix Your Anxiety and Depression with John Wood
In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.
Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?
Ketamine therapy is shaping up to be one of the…
Discussing Extraction and the Colorado Gray Market with Nick Gay
In this episode, Dennis Walker sits down with Nick Gay, the Head of Product Development at Ousia Labs, to talk about what extraction is and why it has become a focus of many entrepreneurs in the psychedelic space, as well as discussing the massive gray market that is developing in Colorado.
![This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF/MMQ) CMPS, MYCOF, NUMI & ATAI, TRIP]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-42-600x338.jpeg)
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF/MMQ) CMPS, MYCOF, NUMI & ATAI, TRIP]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)
Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!
Timestamps:
0:00 – Intro
1:00 – MindMed Begins a Mescaline Study
4:35 – MindMed & The Chopra Foundation
8:30 – Cybin Progresses Phase 2a psilocybin study
11:56 – Mydecine announces Q1 Financials
14:16 – Havn Life Sciences enters the Cluster Headaches Game
16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression
Enjoy!
Links:
MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/
MindMed Partners Up with The Chopra foundation:
https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/
Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/
Mydecine (MYCO / MYCOF) Q1 Financials:
https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update
Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/
Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
https://psychedelicspotlight.com/wake-psilocybin-microdose-study/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #HAVN
Field Trip Uplists to Nasdaq | Cybin to NYSE | Mydecine MDMA Patent: Big Week For Psychedelic Stocks
Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!
On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.
Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.
In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.
Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/
CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/
MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#FieldTripHealth #Cybin #Mydecine